The Implementation of Novel 'Heavy' Water Techniques for Determining Modulation of Muscle Protein, DNA and Lipid Synthesis Due to Ageing

July 30, 2015 updated by: University of Nottingham
Maintenance of body's skeletal muscle is key to a healthy older age. However, as we age we lose on average 1-2% of our muscle each year. In order to slow this loss we need to understand fully the mechanisms regulating muscle mass with ageing. In this project we aim to determine these mechanisms using a new novel technique of 'heavy' water ingestion, which will allow us to measure multiple aspects of skeletal muscle mass control during normal everyday activities in young and old individuals over a period of 6 weeks. We will also determine the influence of resistance exercise training during this period in offsetting declines in muscle with ageing using this method

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Derby, United Kingdom, DE22 3DT
        • Royal Derby Hospital Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Young (18-30y) and old men (65-75y) who are generally healthy and recreationally active

Exclusion Criteria:

  • Active cardiovascular disease
  • Cerebrovascular disease including previous stroke, aneurysm (large vessel or intracranial)
  • Respiratory disease including pulmonary hypertension or COPD
  • Hyper/ hypo parathyroidism, hyper/ hypothyroidism, Cushing's disease, diabetes
  • Active inflammatory bowel disease
  • Renal disease
  • Malignancy
  • Recent steroid treatment (within 6 mo), or hormone replacement therapy
  • Clotting dysfunction
  • Musculoskeletal or neurological disorders
  • Any disease requiring long-term drug prescriptions, including statins

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Old Unilateral Exercise
Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
Experimental: Young Unilateral Exercise
Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle Protein Synthesis
Time Frame: 0-6 Weeks
Comparison of muscle protein synthesis between young and older individuals and in response to 6 weeks unilateral exercise training
0-6 Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle Sub fractions
Time Frame: 0-6 week
Comparison of different sub fractions involved in muscle mass regulation between young and older individuals and in response unilateral exercise training
0-6 week

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle Functions
Time Frame: 0-6 Weeks
Muscle Strength and power un young and older individuals in response to unilateral exercise training
0-6 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Philip Atherton, PhD, AFHEA, University of Nottingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2013

Primary Completion (Actual)

July 1, 2014

Study Completion

December 7, 2022

Study Registration Dates

First Submitted

May 29, 2014

First Submitted That Met QC Criteria

May 30, 2014

First Posted (Estimate)

June 2, 2014

Study Record Updates

Last Update Posted (Estimate)

July 31, 2015

Last Update Submitted That Met QC Criteria

July 30, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • Physoc_D20

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Resistance Exercise

3
Subscribe